Zanzalintinib for colorectal cancer with residual tumor dna
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial is testing a new drug (zanzalintinib) alone or with pembrolizumab to see if it can stop cancer from coming back in people with colorectal cancer who have no visible cancer on scans but still have tumor DNA in their blood.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had stage II or III colon or rectal cancer (not stage IV).
- You have completed your main treatment (surgery, with or without chemo or radiation).
- A blood test shows that small bits of tumor DNA are still present in your blood ('molecular residual disease').
- Your latest CT or MRI scans show no visible cancer anywhere in the body.
- You have not had immunotherapy or VEGF inhibitor drugs before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called zanzalintinib for people with advanced liver cancer (HCC) that can't be treated with surgery. You may join if your cancer has gotten worse after at least one prior treatment, or you couldn't tolerate that treatment.
This trial tests a new drug called zanzalintinib for people with advanced bladder cancer that has grown after at least one prior treatment. The drug may help shrink tumors or slow their growth.
This trial tests a new drug, zanzalintinib, for people with adenoid cystic carcinoma that has come back or spread and can't be treated with local therapy. The drug may help slow or stop the cancer's growth.
This trial tests a new oral drug, zanzalintinib, for men with advanced prostate cancer that has stopped responding to hormone therapy and who have already been treated with Pluvicto. The goal is to see if this drug can slow the cancer's growth.
This study tests a new oral medication called zanzalitinib, which may help slow the growth of advanced prostate cancer that has continued to spread despite hormone therapy and possibly chemotherapy. The goal is to see if the drug is safe and effective for men with this type of cancer.
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.